All the Therapeutic System Drugs
Domapine Agonist. Apomorphine HCl 10 mg/ml. AMPS (sol. for inject): 5 x 2 ml, 5 ml. For
S.C. only. Establish pt on domperidone
20 mg 3 x dly for at least 2 days prior
to initiat. ther. Initiat. should be under
specialist vis. Determinat. thresh.
dose: Inject 1 mg (0.1 ml) S.C. dur.
hypokinet. or “off” period. Observe pt
over 30 mins for motor response. If no
response, give 2nd dose 2 mg (0.2 ml)
S.C., observe for 30 mins. Dose can be
incr. with at least a 40 min-interval
until a satisfact. motor response.
Establish. tmt: A single S.C. inject. into
lower abd. or outer thigh at 1st signs
of “off” episode. Observe pt for the
next hr. Precautions on contin. tmt./
cont. infus: See lit.
PEN FOR INJECT: 5 x 3 ml. For S.C. only.
Pts. select. tmt. should be able to
recognize onset of ‘off’ sympts. and
capable of inject. themselves or have a
respons. caregiver to inject them when
req. As per above.
Tmt. disabl. motor flucts. (“on-off”
phenomena) in Parkinson’s dis. which
persist despite individ. titrat. tmt. with
levodopa (with a periph. decarboxylase
inhibit.) and/or other dopamine
C/I: Respir. depress., dementia, psychot.
dis., hepat. insuffic. Pts who have an ‘on’
response to levodopa that is marred by
severe dyskines./dyston. Known
hypersens. to apomorphine or any
excip. Child, adolesc. under 18 yrs. of
Selective Immunosuppressive Agents. Teriflunomide 14 mg. F.C. TABS.: 28. Recommend. dose 14 mg daily.
Tmt of adult pts. with relaps. remitt.forms
C/I: Hypersens., sev.hep. impair. (Child-
Pugh class C). Pregn., Lact., WOCBA
without use of reliable contracep. Pts.
with sev. Immunodef. states, e.g. AIDS.
Pts. with sign. impair. bone marr. func.,
sign. anaem., leucop., neutrop.
thrombocyt., sev.act. infec.until resolut.
Sev.ren.impair. pts.underg. dialys. Sev.
Hypoproteinaem. e.g. in neph. Syndr.
Vesicular Monoamine Transporter 2. Deutetrabenazine 6,9,12 mg. E.R. TABS.:60. The dose is determ. individ. for each pt. based on reduct. of chorea or tardive dyskines.and tolerab. When first prescribe. to pts. who are not being switch. from tetrabenazine (a related VMAT2 inhib.), the recomm. init. dose is 6 mg admin. oral. once dly. with/ without food for pts. with Huntington’s dis. and
12 mg/d (6 mg ×2/d) for pts. with tard. dyskines.
The dose may be incr. at wkly. intervals in increm. of 6 mg/d to a max. recomm. dly. dosage of 48 mg.
Admin. of total dly. dosages of 12 mg or above in two divid. doses.
The drug should be swall. whole, not chewed, crushed, or broken tabs.
In pts. with risk for QT prolong., the QT interv. should be asses. before and after incr. total dosage above 24 mg/ d. See lit.
Switch. Pts. from Tetrabenazine (Xenazine) to Austedo. See lit.
Indic. in adult. for the tmt. of chorea assoc. with Huntington’s dis.
Indic. in adult. for the tmt. tardive dyskinesia.
C/I: Pts. with Huntington’s dis. who are suicidal, or have untreated or inadequate. treated depres.
Pts. with hep. impair.
Pts. taking reserpine. At least 20 days should elapse after stop. reserpine before starting tmt.
Pts. treat. with MAOIs. Drug should not be used in comb. with an MAOI, or within 14d. of discount. ther. with an MAOI.
Pts. treat. with tetrabenazine (Xenazine) or valbenazine.
Immunomodulator. Interferon Beta-1a 30 mcg. PRE-FILL. SYR/PEN: 4.
SINGLE-USE VIAL: 4. 1 inject I.M. 1 x
wkly (self-inject. permitted).
Relapse form multiple sclerosis, slow
accumulation of physical disabil., decr.
freq. clinical exacerbations. Tmt. demyelinat. event with active inflamm.
process if severe enough to treat with I.V.
corticoster., if alt. diagn. excluded incl.
MRI abnorm. characters. of MS if at high
risk of develop. clin. defin. MS.
C/I: Hypersens. to natural or
recombinant interferon beta, human
albumin or any other component.
Cannabinoids. THC 0.3, 0.9, 1.5, 3, 4.5, 6 mg/drop, CBD 0.6, 0.9, 1.2, 3, 4.5, 6 mg/drop. *This product requires a license for medical cannabis.
BOTTLE. (sublingual drop.): 10gr (330 drops). Dosage should be adjust. individual.
The Israel MOH has outlined in Guidance 106 the 12 indicat. for which med. cannabis is indicated. Accord. to this guidance, the 11 indicat. for this product are:
Chemother-induc. nausea and vomit. (CINV)/ chemother induc. pain.
Metastat. cancer pain.
Spastic. of MS.
Pain in Parkinson's dis.
Cachexia in AIDS.
Recalcitrant epilep. in adult. (Note: Accord. to Guidance 106, med. cannab. is also indic. for recalcitrant epilep. in ped. pts. but this is not an indicat. for this product)
Palliative care for termin. ill pts.
Post- traum. stress disord.
In general, the use of med. cannabis is indicated in pts. who have adequate. tried and failed convent. ther.
Please refer to Guidance 106 for details.
In addition, for an individ. pt. with a clinical. signific. med. condit. that cannot be adequate. managed by convent. ther. and which is not includ. as one of the 12 approved indicat. (eg autism, fibromyalgia), the physician can appeal to the MOH Committee for Med. Cannabis to ask for approval on an individ. exception. basis.
C/I: Prior, current/ family history (1st degr. relative) of psychos. or schizophr. or schizoaffective disord., a hist. of addict. or substance abuse (include. cannabis use disord.or addict. to alcohol), use in preg.or lact., use in pts. <18 yrs. old, bipol.disord., hypersens. to cannabis, coconut oil, palm kernel oil.
In pts. with hepat. cancer, it is recommend. not to use med. cannab. that contains THC.
MAOI-B Inhibitor. Rasagiline (as mesilate) 1 mg. TABS: 10, 30. 1 tab 1 x dly with/without
levodopa, with/without food. Elderly:
No dosage change. Child and
adolescents (under 18 yrs): Not
recommend. Hepat. impair: Severe:
Contraind., Mod: Avoid use; Mild: Use
with caution when initiat. ther. If pt.
progress. from mild to mod. hepat.
impair: Stop ther. Ren. impair: No
Idiopath. Parkinson’s dis. (PD) as
monother. (without levodopa) or as
adjunct. ther. (with levodopa) in pts.
with end of dose fluctuats.
C/I: Hypersens., concom. with other
MAOI’s or pethidine. At least 14 days
should elapse btw. discont. rasagiline
and initiat. MAOI’s or pethidine, severe